Mylan (MYL) Receives FDA Approval for Generic Version of Takeda's Actoplus Met
Bloomberg reporting Mylan (NYSE: MYL) has won FDA approval for its generic version of Takeda's actoplus met.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan (MYL) to Announce Takeover of Meda - FT
- AbbVie (ABBV) Announces Second Elagolix Phase 3 Met co-Primary Endpoints in Endometriosis (NBIX)
- Lannett (LCI) Unit Receives FDA Approval for Generic Temodar Caps
Create E-mail Alert Related CategoriesFDA, Rumors
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!